- Biopharma has historically focused on achieving regulatory approval for value creation
- Asset valuations at the time of licensing or sale can be increased by expanding research plans to address non-regulatory stakeholders
- At the same time, new innovations in R&D productivity can lower the cost of trials while better managing risks of trial success
